Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
Cymabay Therapeutics reports 2019 executive compensation
By ExecPay News
Published: May 15, 2020
Cymabay Therapeutics reported fiscal year 2019 executive compensation information on May 15, 2020.
In 2019, five executives at Cymabay Therapeutics received on average a compensation package of $1.8M, a 1% decrease compared to previous year.
Average pay of disclosed executives at Cymabay Therapeutics
Sujal Shah, Chief Executive Officer, received $2.6M in total, which increased by 32% compared to 2018. 73.90% of Shah's compensation, or $1.9M, was in option awards. Shah also received $153K in non-equity incentive plan, $510K in salary, as well as $4.3K in other compensation.
Janet Dorling, Former Chief Commercial Officer, received a compensation package of $2M. 63.86% of the compensation package, or $1.3M, was in option awards.
Pol Boudes, Chief Medical Officer, earned $1.7M in 2019, a 8% increase compared to previous year.
Charles A. McWherter, Chief Scientific Officer, received $1.5M in 2019, which decreases by 16% compared to 2018.
Klara Dickinson, Chief Regulatory and Compliance Officer, earned $1.2M in 2019.
Related executives
Sujal Shah
Cymabay Therapeutics
Chief Executive Officer
Janet Dorling
Cymabay Therapeutics
Former Chief Commercial Officer
Pol Boudes
Cymabay Therapeutics
Chief Medical Officer
Charles McWherter
Cymabay Therapeutics
Chief Scientific Officer
Klara Dickinson
Cymabay Therapeutics
Chief Regulatory and Compliance Officer
You may also like
Source: SEC filing on May 15, 2020.